Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnan...
Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy
About this item
Full title
Author / Creator
Publisher
England: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central
Subjects
More information
Scope and Contents
Contents
Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women with highly active disease who plan a pregnancy or have an unplanned pregnancy, after accurate counseling abo...
Alternative Titles
Full title
Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d77c15722f4448e59ef05590e7fc8070
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d77c15722f4448e59ef05590e7fc8070
Other Identifiers
ISSN
1824-7288,1720-8424
E-ISSN
1824-7288
DOI
10.1186/s13052-021-01025-4
